Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences.

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Clinical Microbiology

Background:

• Exacerbations significantly impact bronchiectasis (BE) patient outcomes.
• Understanding the differences between pneumonic (CAP) and non-pneumonic (NOCAP) exacerbations in BE is crucial for effective management.
• Limited data exists on the specific microbiological and clinical distinctions between CAP and NOCAP in BE.

Purpose of the Study:

• To compare the clinical and microbiological characteristics of CAP versus NOCAP in adult patients with BE.
• To identify predictors for distinguishing CAP from NOCAP in the BE population.

Main Methods:

• A multicenter prospective observational study was conducted across four Spanish hospitals from 2011 to 2015.
• Consecutive cases of NOCAP and CAP in adult BE patients were recruited and analyzed.
• Clinical data, comorbidities, microbiological findings, and outcomes were collected and compared between the two groups.

Main Results:

• Out of 144 recruited patients, 47 (33%) had CAP. CAP patients were older, more frequently male, and had more comorbidities, including hypertension and COPD.
• While clinical presentation was largely similar, CAP cases showed higher levels of creatinine, C-reactive protein (C-RP), glucose, and leukocytes.
• Streptococcus pneumoniae was the primary cause of CAP, whereas Pseudomonas aeruginosa predominated in NOCAP. A C-RP level of ≥ 8.38 mg/dL significantly predicted CAP.
• Chronic bronchial infection and a history of frequent exacerbations (≥ 2/year) were associated with a lower risk of developing CAP.

Conclusions:

• Pneumonic and non-pneumonic exacerbations in bronchiectasis share similar clinical presentations, with notable differences in fever, leukocytosis, and C-RP levels.
• Microbiological profiles differ between CAP and NOCAP in BE patients.
• A C-reactive protein cutoff value of ≥ 8.38 mg/dL demonstrates predictive value for identifying CAP in bronchiectasis.